Journal of thrombosis and haemostasis : JTH · 2026
Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caudill Elizabeth B, Kim Ju Hee, Kanaan Dareen M, Sylvester Katelyn W, Pimentel Liriany Y, Kim Christine S, Connors Jean M
Аннотация
OBJECTIVE: To evaluate heparin re-exposure practices and safety in patients with prior HIT.
BACKGROUND: Heparin-induced thrombocytopenia (HIT)-associated antibodies are transient, often declining to undetectable levels within approximately 3 to 6 months. Therefore, patients with a remote history of HIT are unlikely to retain immune memory to heparin.
METHODS: This single-center retrospective study evaluated patients with prior HIT admitted between October 1, 2018, and September 30, 2024. HIT was defined as a positive serotonin-release assay result; positive platelet factor 4 immunoassay result with optical density ≥0.4 units or latex immunoturbidimetric assay ≥1 units/mL in the absence of serotonin-release assay and treated as having HIT; or documented diagnosis. The major outcome of this study was incidence of HIT recurrence in patients with a history of HIT who were re-exposed to heparin products on a subsequent admission. Minor outcomes included time from HIT diagnosis to heparin re-exposure, time from re-exposure to HIT recurrence, and incidence of in-hospital mortality, thrombotic event(s), or bleeding event(s) during a recurrent HIT episode.
RESULTS: Of the 35 patients who were re-exposed to heparin products, 1 (2.9%) developed recurrent HIT after 9 days of treatment with intravenous unfractionated heparin, without associated in-hospital mortality, thrombosis, or bleeding. Median time from first HIT diagnosis to heparin re-exposure was 8.1 years (IQR, 2.7-14.2 years).
CONCLUSION: These findings suggest that re-exposure to heparin products in patients with a remote history of HIT may be a safe option for patients requiring parenteral anticoagulation, given the low incidence of HIT recurrence.
BACKGROUND: Heparin-induced thrombocytopenia (HIT)-associated antibodies are transient, often declining to undetectable levels within approximately 3 to 6 months. Therefore, patients with a remote history of HIT are unlikely to retain immune memory to heparin.
METHODS: This single-center retrospective study evaluated patients with prior HIT admitted between October 1, 2018, and September 30, 2024. HIT was defined as a positive serotonin-release assay result; positive platelet factor 4 immunoassay result with optical density ≥0.4 units or latex immunoturbidimetric assay ≥1 units/mL in the absence of serotonin-release assay and treated as having HIT; or documented diagnosis. The major outcome of this study was incidence of HIT recurrence in patients with a history of HIT who were re-exposed to heparin products on a subsequent admission. Minor outcomes included time from HIT diagnosis to heparin re-exposure, time from re-exposure to HIT recurrence, and incidence of in-hospital mortality, thrombotic event(s), or bleeding event(s) during a recurrent HIT episode.
RESULTS: Of the 35 patients who were re-exposed to heparin products, 1 (2.9%) developed recurrent HIT after 9 days of treatment with intravenous unfractionated heparin, without associated in-hospital mortality, thrombosis, or bleeding. Median time from first HIT diagnosis to heparin re-exposure was 8.1 years (IQR, 2.7-14.2 years).
CONCLUSION: These findings suggest that re-exposure to heparin products in patients with a remote history of HIT may be a safe option for patients requiring parenteral anticoagulation, given the low incidence of HIT recurrence.